2020
Phase II study of preoperative chemotherapy with nab-paclitaxel and gemcitabine followed by chemoradiation for borderline resectable or node-positive pancreatic ductal adenocarcinoma.
Chen E, Tormoen G, Kardosh A, Nabavizadeh N, Foster B, Mayo S, Billingsley K, Gilbert E, Lanciault C, Grossberg A, Bensch K, Maynard E, Anderson E, Sheppard B, Thomas C, Lopez C, Vaccaro G. Phase II study of preoperative chemotherapy with nab-paclitaxel and gemcitabine followed by chemoradiation for borderline resectable or node-positive pancreatic ductal adenocarcinoma. Journal Of Clinical Oncology 2020, 38: 697-697. DOI: 10.1200/jco.2020.38.4_suppl.697.Peer-Reviewed Original ResearchGemcitabine/nab-paclitaxelPancreatic ductal adenocarcinomaResectable pancreatic ductal adenocarcinomaPre-operative therapyPre-operative treatmentNab-paclitaxelPancreatic resectionDuctal adenocarcinomaBorderline resectable pancreatic ductal adenocarcinomaSingle-arm phase II trialNab-paclitaxel chemotherapyPositive clinical nodesPhase II studyR0 resection ratePhase II trialNegative surgical marginsRelapse-free survivalMicro-metastatic diseaseIntensity-modulated radiation therapyGemcitabine 1000II trialPrimary endpointResection rateSecondary endpointsII study
2018
Epirubicin and Ifosfamide with Preoperative Radiation for High-Risk Soft Tissue Sarcomas
Lu E, Perlewitz KS, Hayden JB, Hung AY, Doung YC, Davis LE, Mansoor A, Vetto JT, Billingsley KG, Kaempf A, Park B, Ryan CW. Epirubicin and Ifosfamide with Preoperative Radiation for High-Risk Soft Tissue Sarcomas. Annals Of Surgical Oncology 2018, 25: 920-927. PMID: 29388122, DOI: 10.1245/s10434-018-6346-4.Peer-Reviewed Original ResearchConceptsSoft tissue sarcomasHigh-risk soft tissue sarcomasPhase II studyII studyPreoperative radiationTissue sarcomasHigh-grade soft tissue sarcomasHigh-risk STS patientsDistant disease-free survivalM2/dayExtensive institutional experienceLocal-regional failureDisease-free survivalRetrospective chart reviewDose-intense chemotherapyFavorable clinical outcomePercent of tumorsGy of radiationPostoperative cyclesTrimodality therapyPreoperative therapyWound complicationsChart reviewOverall survivalPathologic response
2015
S0713: A phase II study of cetuximab (CET) added to induction chemotherapy (ICT) of oxaliplatin (OX) and capecitabine (CAP), followed by neoadjuvant chemoradiation (NACR) for locally advanced rectal cancer (LARC).
Leichman C, McDonough S, Smalley S, Billingsley K, Lenz H, Beldner M, Hezel A, Velasco M, Guthrie K, Blanke C, Hochster H. S0713: A phase II study of cetuximab (CET) added to induction chemotherapy (ICT) of oxaliplatin (OX) and capecitabine (CAP), followed by neoadjuvant chemoradiation (NACR) for locally advanced rectal cancer (LARC). Journal Of Clinical Oncology 2015, 33: 3516-3516. DOI: 10.1200/jco.2015.33.15_suppl.3516.Peer-Reviewed Original Research